<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>The Price of Access — Havellum Institute for Health Policy & Clinical Economics</title>
<meta name="description" content="Havellum Report HV-2025-07: Specialty drug affordability, benefit-design erosion, and administrative burden in American health care.">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Merriweather:ital,wght@0,400;0,700;0,900;1,400;1,700&family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
<script src="https://cdn.jsdelivr.net/npm/chart.js@4.4.1/dist/chart.umd.min.js"></script>
<style>
:root{
--navy:#1e3a8a;
--ink:#111827;
--paper:#ffffff;
--line:rgba(17,24,39,.14);
--n08:rgba(30,58,138,.07);
--n15:rgba(30,58,138,.14);
--n35:rgba(30,58,138,.35);
--serif:'Merriweather',Georgia,serif;
--sans:'Inter',system-ui,-apple-system,sans-serif;
}
*{margin:0;padding:0;box-sizing:border-box}
html{scroll-behavior:smooth}
body{
font-family:var(--sans);
color:var(--ink);
background:var(--paper);
font-size:16.5px;
line-height:1.78;
-webkit-font-smoothing:antialiased;
overflow-x:hidden;
}
/* film-grain overlay */
body::after{
content:"";position:fixed;inset:0;z-index:120;pointer-events:none;opacity:.035;
background-image:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='160' height='160'%3E%3Cfilter id='n'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.9' numOctaves='2'/%3E%3C/filter%3E%3Crect width='160' height='160' filter='url(%23n)'/%3E%3C/svg%3E");
}
::selection{background:var(--navy);color:#fff}
a{color:var(--navy);text-decoration:none}
p{margin-bottom:1.05em}
sup{font-size:.62em;color:var(--navy);font-weight:600}
/* ---------- progress bar ---------- */
#progress{position:fixed;top:0;left:0;height:3px;width:0;background:var(--navy);z-index:200;transition:width .08s linear}
/* ---------- masthead ---------- */
.masthead{border-bottom:3px double var(--navy);background:#fff;position:relative;z-index:5}
.masthead .rule-thin{height:1px;background:var(--navy);margin-bottom:3px}
.mast-inner{max-width:1240px;margin:0 auto;padding:22px 28px 16px;display:flex;align-items:flex-end;justify-content:space-between;gap:24px;flex-wrap:wrap}
.wordmark{font-family:var(--serif);font-weight:900;font-size:34px;letter-spacing:.14em;color:var(--ink);text-transform:uppercase;line-height:1}
.wordmark em{font-style:normal;color:var(--navy)}
.mast-right{text-align:right;font-size:11px;letter-spacing:.16em;text-transform:uppercase;color:rgba(17,24,39,.72);line-height:1.8}
.mast-right b{color:var(--navy)}
/* ---------- ticker ---------- */
.ticker{background:var(--navy);color:#fff;overflow:hidden;border-bottom:1px solid #fff;position:relative}
.ticker::before,.ticker::after{content:"";position:absolute;top:0;bottom:0;width:70px;z-index:2;pointer-events:none}
.ticker::before{left:0;background:linear-gradient(90deg,var(--navy),rgba(30,58,138,0))}
.ticker::after{right:0;background:linear-gradient(270deg,var(--navy),rgba(30,58,138,0))}
.ticker-label{position:absolute;left:0;top:0;bottom:0;z-index:3;display:flex;align-items:center;padding:0 16px;background:#111827;font-size:10px;letter-spacing:.22em;font-weight:700}
.ticker-track{display:flex;gap:56px;white-space:nowrap;padding:9px 0;font-size:12.5px;letter-spacing:.06em;font-variant-numeric:tabular-nums;animation:tick 52s linear infinite;will-change:transform}
.ticker:hover .ticker-track{animation-play-state:paused}
.ticker-track span b{font-weight:700}
.ticker-track span i{font-style:normal;opacity:.65;margin-right:8px}
@keyframes tick{from{transform:translateX(0)}to{transform:translateX(-50%)}}
/* ---------- hero / title block ---------- */
.hero{max-width:1240px;margin:0 auto;padding:64px 28px 44px;position:relative}
.hero .overline{font-size:11px;letter-spacing:.28em;text-transform:uppercase;color:var(--navy);font-weight:700;margin-bottom:22px;display:flex;align-items:center;gap:14px}
.hero .overline::after{content:"";height:1px;flex:1;background:var(--n35)}
h1.report-title{font-family:var(--serif);font-weight:900;font-size:clamp(34px,5.4vw,66px);line-height:1.12;letter-spacing:-.01em;color:var(--ink);max-width:1050px}
h1 .line{display:block;overflow:hidden;padding-bottom:.06em}
h1 .line-inner{display:block;transform:translateY(112%);animation:rise .95s cubic-bezier(.19,.66,.22,1) forwards}
h1 .line:nth-child(2) .line-inner{animation-delay:.14s}
h1 .line:nth-child(3) .line-inner{animation-delay:.28s}
@keyframes rise{to{transform:translateY(0)}}
.standfirst{font-family:var(--serif);font-style:italic;font-size:clamp(17px,2vw,21px);line-height:1.65;color:rgba(17,24,39,.86);max-width:840px;margin-top:26px;border-left:3px solid var(--navy);padding-left:22px}
.hero-meta{display:flex;flex-wrap:wrap;gap:10px;margin-top:30px}
.chip{border:1px solid var(--n35);padding:7px 15px;font-size:11px;letter-spacing:.14em;text-transform:uppercase;color:var(--ink);background:var(--n08);transition:background .3s,color .3s,border-color .3s}
.chip:hover{background:var(--navy);color:#fff;border-color:var(--navy)}
.chip b{color:var(--navy)}
.chip:hover b{color:#fff}
/* ---------- executive summary ---------- */
.exec-summary{background:var(--navy);color:#fff}
.exec-inner{max-width:1240px;margin:0 auto;padding:54px 28px;display:grid;grid-template-columns:1.25fr .9fr;gap:56px}
.exec-inner h2{font-family:var(--serif);font-size:15px;letter-spacing:.24em;text-transform:uppercase;font-weight:700;margin-bottom:22px;padding-bottom:12px;border-bottom:1px solid rgba(255,255,255,.35)}
.exec-inner .ab-block{margin-bottom:18px}
.exec-inner .ab-block h3{font-size:11px;letter-spacing:.22em;text-transform:uppercase;color:rgba(255,255,255,.72);margin-bottom:6px;font-weight:700}
.exec-inner .ab-block p{font-size:15px;line-height:1.7;color:rgba(255,255,255,.94)}
.exec-facts{border-left:1px solid rgba(255,255,255,.28);padding-left:48px}
.exec-facts .fact{margin-bottom:22px}
.exec-facts .fact .k{font-size:11px;letter-spacing:.2em;text-transform:uppercase;color:rgba(255,255,255,.7)}
.exec-facts .fact .v{font-family:var(--serif);font-weight:900;font-size:30px;line-height:1.15}
.exec-facts .fact .d{font-size:12.5px;color:rgba(255,255,255,.75)}
/* ---------- KPI cards ---------- */
.kpis{max-width:1240px;margin:-1px auto 0;padding:0 28px;position:relative;z-index:4}
.kpi-grid{display:grid;grid-template-columns:repeat(6,1fr);gap:14px;transform:translateY(-38px)}
.kpi{background:#fff;border:1px solid var(--line);border-top:3px solid var(--navy);padding:20px 18px 16px;transition:transform .35s,box-shadow .35s}
.kpi:hover{transform:translateY(-5px);box-shadow:0 18px 34px -18px rgba(30,58,138,.45)}
.kpi .lbl{font-size:10px;letter-spacing:.18em;text-transform:uppercase;color:rgba(17,24,39,.62);margin-bottom:10px;line-height:1.5}
.kpi .num{font-family:var(--serif);font-weight:900;font-size:clamp(22px,2vw,30px);color:var(--navy);font-variant-numeric:tabular-nums;line-height:1.1}
.kpi .sub{font-size:11.5px;color:rgba(17,24,39,.7);margin-top:8px;line-height:1.5}
/* ---------- layout ---------- */
.wrap{max-width:1240px;margin:0 auto;padding:20px 28px 90px;display:grid;grid-template-columns:228px minmax(0,1fr);gap:60px;align-items:start}
.toc{position:sticky;top:28px;font-size:12.5px;border-left:1px solid var(--line);padding-left:20px}
.toc h4{font-size:10px;letter-spacing:.26em;text-transform:uppercase;color:var(--navy);margin-bottom:14px;font-weight:700}
.toc a{display:block;padding:7px 0;color:rgba(17,24,39,.72);border-left:2px solid transparent;margin-left:-22px;padding-left:20px;transition:color .25s,border-color .25s;line-height:1.45}
.toc a:hover,.toc a.active{color:var(--navy);border-left-color:var(--navy)}
.toc a .n{font-weight:700;margin-right:7px;font-variant-numeric:tabular-nums}
.toc-note{margin-top:22px;padding-top:16px;border-top:1px solid var(--line);font-size:11px;color:rgba(17,24,39,.55);line-height:1.6}
main{min-width:0}
section{margin-bottom:88px;scroll-margin-top:40px}
.sec-head{display:grid;grid-template-columns:auto 1fr;gap:26px;align-items:baseline;margin-bottom:30px;padding-bottom:18px;border-bottom:2px solid var(--ink)}
.sec-num{font-family:var(--serif);font-weight:900;font-size:clamp(46px,5vw,74px);line-height:.85;color:transparent;-webkit-text-stroke:1.5px var(--navy);opacity:.9}
.sec-title{font-family:var(--serif);font-weight:900;font-size:clamp(24px,3vw,36px);line-height:1.2;color:var(--ink)}
.sec-title small{display:block;font-family:var(--sans);font-weight:600;font-size:11px;letter-spacing:.24em;text-transform:uppercase;color:var(--navy);margin-bottom:8px}
main h3{font-family:var(--serif);font-size:21px;font-weight:700;margin:36px 0 14px;color:var(--ink);line-height:1.35}
main h3 .h3-n{color:var(--navy);margin-right:10px;font-variant-numeric:tabular-nums}
main h4{font-size:12px;letter-spacing:.2em;text-transform:uppercase;color:var(--navy);margin:26px 0 10px;font-weight:700}
.lede{font-size:18.5px;line-height:1.75;color:var(--ink)}
.lede::first-letter{font-family:var(--serif);font-weight:900;font-size:3.4em;float:left;line-height:.82;padding:6px 12px 0 0;color:var(--navy)}
.two-col{column-count:2;column-gap:44px;column-rule:1px solid var(--line)}
.two-col p{break-inside:avoid}
/* callouts */
.callout{border-left:3px solid var(--navy);background:var(--n08);padding:22px 26px;margin:30px 0;position:relative}
.callout::before{content:attr(data-tag);position:absolute;top:-10px;left:18px;background:var(--navy);color:#fff;font-size:10px;letter-spacing:.2em;font-weight:700;padding:3px 12px;text-transform:uppercase}
.callout p{font-size:15px;margin-bottom:0}
.callout p + p{margin-top:10px}
.callout.dark{background:var(--navy);border-color:var(--ink)}
.callout.dark p{color:rgba(255,255,255,.95)}
.callout.dark::before{background:#111827}
/* figures */
figure.chart-card{border:1px solid var(--line);background:#fff;margin:34px 0;position:relative}
figure.chart-card .fc-head{display:flex;justify-content:space-between;align-items:center;gap:16px;padding:16px 22px;border-bottom:1px solid var(--line);flex-wrap:wrap}
.fc-tag{font-size:10.5px;letter-spacing:.22em;font-weight:700;color:var(--navy);text-transform:uppercase}
.fc-title{font-family:var(--serif);font-weight:700;font-size:15.5px}
.canvas-wrap{padding:22px 22px 10px;height:400px;position:relative}
.canvas-wrap.short{height:340px}
.canvas-wrap.tall{height:440px}
figcaption{padding:14px 22px 20px;font-size:12.5px;color:rgba(17,24,39,.72);line-height:1.65;border-top:1px dashed var(--line)}
figcaption b{color:var(--navy);letter-spacing:.14em;font-size:10.5px;text-transform:uppercase}
.quad-legend{display:flex;flex-wrap:wrap;gap:8px 20px;padding:0 22px 16px;font-size:11.5px;color:rgba(17,24,39,.8)}
.quad-legend span::before{content:"";display:inline-block;width:9px;height:9px;margin-right:7px;background:var(--navy)}
.quad-legend span:nth-child(2)::before{opacity:.6}
.quad-legend span:nth-child(3)::before{opacity:.35}
.quad-legend span:nth-child(4)::before{background:var(--ink)}
/* tables */
.tbl-wrap{overflow-x:auto;margin:32px 0;border:1px solid var(--line)}
table{width:100%;border-collapse:collapse;font-size:13.5px;min-width:680px}
caption{text-align:left;padding:14px 18px;font-size:12.5px;color:rgba(17,24,39,.72);background:var(--n08);border-bottom:1px solid var(--line);line-height:1.6}
caption b{color:var(--navy);letter-spacing:.16em;font-size:10.5px;text-transform:uppercase;display:block;margin-bottom:3px}
th{background:var(--navy);color:#fff;text-align:left;padding:12px 16px;font-size:10.5px;letter-spacing:.16em;text-transform:uppercase;font-weight:600}
td{padding:11px 16px;border-bottom:1px solid var(--line);vertical-align:top;line-height:1.55}
tbody tr{transition:background .25s}
tbody tr:hover{background:var(--n08)}
td.num{text-align:right;font-variant-numeric:tabular-nums;font-weight:600}
td .bar{height:5px;background:var(--n15);margin-top:6px;position:relative;overflow:hidden}
td .bar i{position:absolute;inset:0;background:var(--navy);width:var(--w);transition:width 1.2s cubic-bezier(.2,.6,.2,1)}
/* image duotone */
.duo{position:relative;background:var(--navy);overflow:hidden;margin:34px 0;border:1px solid var(--line)}
.duo img{width:100%;display:block;filter:grayscale(1) contrast(1.08) brightness(1.06);mix-blend-mode:lighten;transform:scale(1.04);transition:transform 1.4s cubic-bezier(.2,.6,.2,1)}
.duo:hover img{transform:scale(1.09)}
.duo .duo-cap{position:absolute;left:0;bottom:0;background:#111827;color:#fff;font-size:10.5px;letter-spacing:.18em;text-transform:uppercase;padding:8px 16px}
/* recommendations */
.rec{display:grid;grid-template-columns:70px 1fr;gap:20px;padding:22px 0;border-bottom:1px solid var(--line);transition:background .3s,padding-left .3s}
.rec:hover{background:var(--n08);padding-left:14px;margin-left:-14px}
.rec .r-n{font-family:var(--serif);font-weight:900;font-size:34px;color:transparent;-webkit-text-stroke:1.3px var(--navy);line-height:1}
.rec h5{font-family:var(--serif);font-size:17px;font-weight:700;margin-bottom:6px}
.rec p{font-size:14.5px;margin:0;line-height:1.68}
.rec .r-scope{display:inline-block;font-size:9.5px;letter-spacing:.2em;text-transform:uppercase;color:var(--navy);font-weight:700;border:1px solid var(--n35);padding:2px 9px;margin-bottom:8px}
/* references */
ol.refs{list-style:none;counter-reset:ref;font-size:13px;line-height:1.66}
ol.refs li{counter-increment:ref;padding:9px 0 9px 44px;position:relative;border-bottom:1px solid var(--n08)}
ol.refs li::before{content:counter(ref) ".";position:absolute;left:8px;color:var(--navy);font-weight:700}
/* reveal */
[data-reveal]{opacity:0;transform:translateY(22px);transition:opacity .8s ease,transform .8s cubic-bezier(.2,.6,.2,1)}
[data-reveal].in{opacity:1;transform:none}
/* footer */
footer{background:#111827;color:rgba(255,255,255,.85)}
.foot-inner{max-width:1240px;margin:0 auto;padding:58px 28px 34px;display:grid;grid-template-columns:1.3fr 1fr 1fr;gap:44px}
.foot-inner h5{font-size:10.5px;letter-spacing:.24em;text-transform:uppercase;color:#fff;margin-bottom:14px;border-bottom:1px solid rgba(255,255,255,.25);padding-bottom:10px}
.foot-inner p,.foot-inner li{font-size:12.5px;line-height:1.7;color:rgba(255,255,255,.72)}
.foot-inner ul{list-style:none}
.foot-word{font-family:var(--serif);font-weight:900;font-size:26px;letter-spacing:.14em;color:#fff;text-transform:uppercase;margin-bottom:12px}
.foot-word em{font-style:normal;color:rgba(255,255,255,.55)}
.foot-base{border-top:1px solid rgba(255,255,255,.18);padding:18px 28px;max-width:1240px;margin:0 auto;display:flex;justify-content:space-between;gap:20px;flex-wrap:wrap;font-size:11px;letter-spacing:.12em;text-transform:uppercase;color:rgba(255,255,255,.5)}
@media(max-width:1080px){
.kpi-grid{grid-template-columns:repeat(3,1fr)}
.wrap{grid-template-columns:1fr;gap:24px}
.toc{position:static;display:flex;flex-wrap:wrap;gap:2px 18px;border-left:none;border-top:2px solid var(--ink);padding:16px 0 0}
.toc h4{width:100%}
.toc a{margin-left:0;padding-left:0;border-left:none}
.toc-note{display:none}
.exec-inner{grid-template-columns:1fr}
.exec-facts{border-left:none;padding-left:0;border-top:1px solid rgba(255,255,255,.28);padding-top:30px;display:grid;grid-template-columns:1fr 1fr;gap:10px 30px}
.two-col{column-count:1}
}
@media(max-width:640px){
.kpi-grid{grid-template-columns:repeat(2,1fr);transform:translateY(-28px)}
.sec-head{grid-template-columns:1fr}
.canvas-wrap{height:320px}
.foot-inner{grid-template-columns:1fr}
}
@media(prefers-reduced-motion:reduce){
*,*::before,*::after{animation:none!important;transition:none!important}
h1 .line-inner{transform:none}
[data-reveal]{opacity:1;transform:none}
.ticker-track{animation:none;overflow-x:auto}
html{scroll-behavior:auto}
}
</style>
</head>
<body>
<div id="progress" aria-hidden="true"></div>
<!-- ============ MASTHEAD ============ -->
<header class="masthead">
<div class="rule-thin"></div>
<div class="mast-inner">
<div class="wordmark">Have<em>llum</em></div>
<div class="mast-right">
<b>Institute for Health Policy & Clinical Economics</b><br>
Report No. HV-2025-07 · Peer-Review Draft 4.2 · Washington / Baltimore Editorial Office<br>
Classification: Policy Analysis — Modeled Data Disclosure Enclosed
</div>
</div>
<div class="ticker" aria-label="Drug price and premium ticker">
<div class="ticker-label">WAC / PREMIUM WIRE</div>
<div class="ticker-track" id="tickerTrack"></div>
</div>
</header>
<!-- ============ HERO ============ -->
<div class="hero">
<div class="overline">Medical Research & Healthcare Economics Report · IMRAD Format · AMA Style</div>
<h1 class="report-title">
<span class="line"><span class="line-inner">The Price of Access:</span></span>
<span class="line"><span class="line-inner">Specialty Drug Affordability, Benefit-Design Erosion,</span></span>
<span class="line"><span class="line-inner">and the Administrative Burden of American Care</span></span>
</h1>
<p class="standfirst">An integrated clinical–economic analysis of how list-price therapeutics — led by GLP-1 receptor agonists — collide with rising premiums, high-deductible benefit design, and opaque pricing to produce functional access failure among patients managing insomnia, migraine, trauma-spectrum illness, and postoperative recovery.</p>
<div class="hero-meta">
<span class="chip">Issued by <b>Havellum</b></span>
<span class="chip">Cohort <b>HSBC-2025 · n = 12,480</b></span>
<span class="chip">Horizon <b>FY2015 – FY2028</b></span>
<span class="chip">Figures <b>6 Interactive · Tables 4</b></span>
<span class="chip">References <b>22 · AMA 11th ed.</b></span>
</div>
</div>
<!-- ============ EXECUTIVE SUMMARY ============ -->
<div class="exec-summary" id="abstract">
<div class="exec-inner">
<div data-reveal>
<h2>Executive Summary — Structured Abstract</h2>
<div class="ab-block"><h3>Background</h3><p>Affordability has displaced availability as the binding constraint on American health care. Wholesale acquisition costs for glucagon-like peptide–1 receptor agonists (GLP-1 RAs) commonly exceed $12,000 to $16,200 per year before coverage, while employer-sponsored premiums and deductibles have outpaced median wage growth for more than a decade. Patients with chronic insomnia, migraine, trauma-spectrum disorders, and postoperative recovery trajectories face compounding exposure because these conditions cluster, recur, and demand sustained pharmacotherapy.</p></div>
<div class="ab-block"><h3>Methods</h3><p>We constructed the Havellum Synthetic Beneficiary Cohort (HSBC-2025), a microsimulation of 12,480 commercially insured and Medicare-eligible beneficiaries anchored to published benchmarks from the KFF Employer Health Benefits Survey, CMS National Health Expenditure accounts, and federal negotiation program disclosures. Cost-sharing cascades, exemption-request pipelines, and policy milestones were modeled across FY2015–FY2028.</p></div>
<div class="ab-block"><h3>Key Findings</h3><p>Median annual out-of-pocket exposure for a beneficiary concurrently using a GLP-1 RA, a calcitonin gene–related peptide (CGRP) inhibitor, and a dual orexin receptor antagonist reached $5,950 before catastrophic protections engaged — 8.4% of median household income in the cohort. Exemption and waiver pipelines lost 42.0% of filed requests before sustained approval. Administrative processing consumed an estimated 27.3% of hospital revenue in the modeled systems, and price-transparency compliance remained materially incomplete.</p></div>
<div class="ab-block"><h3>Conclusions</h3><p>Affordability failure is a systems-engineering problem, not a single-price problem. Health systems, employers, and academic institutions should treat list price, benefit design, and administrative friction as one coupled mechanism — and deploy navigation, reference pricing, structured documentation, and transparency enforcement accordingly.</p></div>
</div>
<aside class="exec-facts" data-reveal>
<div class="fact"><div class="k">Median Annual OOP Exposure (Modeled)</div><div class="v">$5,950</div><div class="d">Triple-therapy beneficiary, pre-catastrophic</div></div>
<div class="fact"><div class="k">Average Single Premium, 2024</div><div class="v">$8,951</div><div class="d">+6.2% YoY; wages +4.3%, inflation +3.5%<sup>1</sup></div></div>
<div class="fact"><div class="k">GLP-1 List-Price Range</div><div class="v">$12.7–16.2K</div><div class="d">Annual WAC before rebates & discounts</div></div>
<div class="fact"><div class="k">Exemption Pipeline Attrition</div><div class="v">42.0%</div><div class="d">Filed → sustained approval, 12-month horizon</div></div>
<div class="fact"><div class="k">IRA-Selected Drugs, Round 1</div><div class="v">10</div><div class="d">Negotiated prices effective 2026; −25% to −79%<sup>4</sup></div></div>
</aside>
</div>
</div>
<!-- ============ KPI CARDS ============ -->
<div class="kpis">
<div class="kpi-grid">
<div class="kpi" data-reveal><div class="lbl">Family Premium, 2024 Avg</div><div class="num" data-count="25570" data-prefix="$">$0</div><div class="sub">+7.0% vs FY2023 (KFF survey)<sup>1</sup></div></div>
<div class="kpi" data-reveal data-delay="60"><div class="lbl">Avg Annual HDHP Deductible</div><div class="num" data-count="1787" data-prefix="$">$0</div><div class="sub">Single coverage, high-deductible plans<sup>1,22</sup></div></div>
<div class="kpi" data-reveal data-delay="120"><div class="lbl">Wegovy 2.4 mg WAC</div><div class="num" data-count="1349.02" data-decimals="2" data-prefix="$">$0</div><div class="sub">Per month, list price before rebates<sup>5</sup></div></div>
<div class="kpi" data-reveal data-delay="180"><div class="lbl">Cost-Related Nonadherence</div><div class="num" data-count="41.2" data-decimals="1" data-suffix="%">0%</div><div class="sub">Cohort w/ ≥1 chronic condition (modeled)</div></div>
<div class="kpi" data-reveal data-delay="240"><div class="lbl">Administrative Cost Share</div><div class="num" data-count="27.3" data-decimals="1" data-suffix="%">0%</div><div class="sub">Modeled hospital revenue consumed<sup>19</sup></div></div>
<div class="kpi" data-reveal data-delay="300"><div class="lbl">IRA Round-2 Negotiations</div><div class="num" data-count="15">0</div><div class="sub">Drugs selected for 2026 price setting<sup>4</sup></div></div>
</div>
</div>
<!-- ============ BODY ============ -->
<div class="wrap">
<nav class="toc" aria-label="Report contents">
<h4>In This Report</h4>
<a href="#s1"><span class="n">1</span>Title & Executive Overview</a>
<a href="#s2"><span class="n">2</span>Clinical & Epidemiological Context</a>
<a href="#s3"><span class="n">3</span>Socio-Legal & Institutional Frameworks</a>
<a href="#s4"><span class="n">4</span>Empirical Analysis & Visualizations</a>
<a href="#s5"><span class="n">5</span>Ethics, Privacy & Conflict Resolution</a>
<a href="#s6"><span class="n">6</span>Strategic Recommendations</a>
<a href="#s7"><span class="n">7</span>Conclusion & References</a>
<div class="toc-note">Havellum methodology note: all cohort figures are modeled estimates built on publicly reported benchmarks and are disclosed as synthetic where marked.</div>
</nav>
<main>
<!-- ================= SECTION 1 ================= -->
<section id="s1">
<div class="sec-head" data-reveal>
<div class="sec-num">01</div>
<div class="sec-title"><small>Section I · Introduction</small>Title & Executive Overview</div>
</div>
<p class="lede" data-reveal>American health care has achieved a paradox: unprecedented therapeutic capability paired with declining financial access to it. The decade produced curative antivirals, disease-modifying obesity therapies, targeted migraine biologics, and refined perioperative pathways — and simultaneously produced a benefit environment in which the median commercially insured family now confronts premiums near $25,570, deductibles that routinely exceed $1,700, and list prices for single agents that can exceed a household's entire annual health budget.<sup>1,2</sup> The question before policymakers, health systems, and employers is therefore no longer whether effective care exists, but whether the financing architecture transmits it to the patient at a price compatible with adherence.</p>
<p data-reveal>This report, prepared by the Havellum Institute for Health Policy & Clinical Economics, examines that transmission failure across three coupled layers. The first layer is the <em>price layer</em>: wholesale acquisition costs, rebates, and net pricing for high-visibility specialty classes — above all the GLP-1 receptor agonists (semaglutide, tirzepatide) whose cultural and clinical prominence has made them the defining affordability controversy of the 2020s.<sup>5,6</sup> The second is the <em>benefit-design layer</em>: premium growth, deductible escalation, copay-accumulator programs, and formulary exclusion that determine what share of the price layer reaches the patient's checking account. The third is the <em>administrative layer</em>: prior authorization, exemption and waiver pipelines under the Americans with Disabilities Act (ADA), the Family and Medical Leave Act (FMLA), National Collegiate Athletic Association (NCAA) medical-waiver regimes, and employer coverage waivers — a largely invisible tax of documentation, delay, and denial that functions as a de facto utilization control.</p>
<p data-reveal>The analytical core of the report is the Havellum Synthetic Beneficiary Cohort (HSBC-2025), a microsimulation of 12,480 beneficiaries constructed to mirror published epidemiology and benefit benchmarks. We deliberately modeled four high-prevalence, high-recurrence condition families — chronic insomnia, migraine, trauma-spectrum illness, and postoperative recovery — because they are the conditions in which affordability decisions are made most frequently, most repetitively, and with the most direct consequences for labor force participation. Section 2 establishes the clinical and epidemiological context; Section 3 maps the socio-legal frameworks that mediate access; Section 4 presents the empirical results across six interactive visualizations; Section 5 addresses the ethical, privacy, and dispute-resolution tensions these systems create; Section 6 issues ten strategic recommendations; and Section 7 concludes with AMA-formatted references.</p>
<div class="callout" data-tag="Core Thesis" data-reveal>
<p>Affordability is not a property of any single invoice. It is an emergent property of the interaction between list price, benefit design, and administrative friction. Interventions aimed at any one layer while ignoring the other two will be absorbed by the system — rebates will widen spreadsheets without narrowing copays, and transparency rules will publish prices that no benefit design actually pays. The Havellum position is that health systems, employers, and academic institutions must manage all three layers as a single coupled mechanism.</p>
</div>
</section>
<!-- ================= SECTION 2 ================= -->
<section id="s2">
<div class="sec-head" data-reveal>
<div class="sec-num">02</div>
<div class="sec-title"><small>Section II · Background</small>Clinical Background & Epidemiological Context</div>
</div>
<p class="lede" data-reveal>The four condition families examined here were selected because they share a consequential architecture: high prevalence, chronic or recurrent courses, dependence on sustained pharmacotherapy, and substantial — but contestable — functional impairment. Each sits at a different point of the affordability spectrum, from near-generic commodity drugs to biologics priced at five figures, which makes them an ideal instrument for isolating where cost actually blocks care.</p>
<div class="duo" data-reveal>
<img src="https://picsum.photos/seed/specialty-pharmacy-shelves/1600/520" alt="Illustrative specialty pharmacy interior" loading="lazy">
<div class="duo-cap">Illustrative — Specialty Pharmacy Dispensing Environment</div>
</div>
<h3 data-reveal><span class="h3-n">2.1</span>Chronic Insomnia: The Under-Priced, Under-Treated Baseline</h3>
<p data-reveal>Chronic insomnia disorder affects roughly 10% to 30% of adults depending on diagnostic stringency, with comorbidity concentrated in exactly the populations this report models: patients with migraine, post-traumatic stress, and postoperative pain states.<sup>14</sup> Its economic signature is unusual. Direct pharmacologic cost is comparatively low — doxepin, trazodone, and compounded melatonin regimens sit at the generic end of the market — yet the newest mechanistic class, the dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant), carries monthly list prices in the $400–$600 range, placing them squarely in deductible-exposure territory for high-deductible health plan (HDHP) enrollees.<sup>14</sup> The dominant economic harm of insomnia is indirect: presenteeism, error rates, and situational exacerbation under shift work and caregiving schedules. In the HSBC-2025 cohort, insomnia beneficiaries filed accommodation requests at nearly twice the rate of matched controls, most commonly seeking schedule flexibility and environmental sleep hygiene modifications — interventions that are inexpensive to grant but administratively costly to document.</p>
<h3 data-reveal><span class="h3-n">2.2</span>Migraine: A Biologic Era Meets a Generic-Era Benefit Design</h3>
<p data-reveal>An estimated 39 million Americans experience migraine; roughly one-third of eligible patients meet criteria for preventive therapy, and the condition accounts for a substantial share of neurological disability-adjusted life-years in working-age adults.<sup>15,16</sup> The therapeutic landscape bifurcates sharply by price. Triptans and older preventives (topiramate, propranolol, amitriptyline) are generic and inexpensive. The CGRP-targeted monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and the oral gepants (rimegepant, atogepant) price at approximately $7,000 to $10,500 per year at list.<sup>16</sup> This bifurcation makes migraine a natural experiment in step therapy: nearly every commercial payer enforces failure of two or three generic preventives before approving a CGRP agent, a sequence that typically consumes four to nine months of ongoing disability. In the cohort, median time from first preventive indication to CGRP initiation was 214 days among commercially insured beneficiaries — a delay that is simultaneously clinical, economic, and administrative in origin.</p>
<h3 data-reveal><span class="h3-n">2.3</span>Trauma-Spectrum Illness: Documentation as a Second Injury</h3>
<p data-reveal>Lifetime prevalence of post-traumatic stress disorder in US adults approximates 6% to 7%, with markedly higher concentrations in populations intersecting the justice, military-transition, and collegiate-athletics systems examined later in this report.<sup>17</sup> Pharmacotherapy (SSRIs, SNRIs, prazosin for trauma-associated nightmares) is inexpensive; the affordability problem in trauma care is the psychotherapy and continuity bundle — prolonged exposure, cognitive processing therapy, and EMDR delivered in 12- to 16-session arcs that network adequacy and visit-limit benefit designs routinely interrupt. Trauma-informed clinical waivers, the institutional instrument through which patients obtain modified scheduling, examination protocols, or temporary duty relief, impose a documentation burden that can itself be re-traumatizing when poorly designed. The cohort modeled trauma-informed waiver requests as a distinct pipeline stage and found them the most delay-prone category: median 41 days from filing to decision, versus 24 days for all other categories, driven by the clinical-review intensity required to substantiate non-permanent functional impairment without excessive disclosure.</p>
<h3 data-reveal><span class="h3-n">2.4</span>Postoperative Recovery: The Episode Where Every Deductible Resets</h3>
<p data-reveal>Surgical episodes concentrate affordability stress into a single quarter. Enhanced Recovery After Surgery (ERAS) protocols have demonstrably reduced length of stay and opioid exposure, yet the residual episode — anesthesia, imaging, post-acute physical therapy, and increasingly common non-opioid adjunctive analgesics — routinely generates multi-party billing in which out-of-network ancillary providers bill into in-network episodes.<sup>18</sup> The No Surprises Act mitigated the most acute balance-billing scenarios, but its independent dispute resolution mechanism has been litigated into partial instability, and the cohort still showed median surprise-bill exposure of $760 per surgical episode after adjustments. Postoperative insomnia and migraine exacerbation are common sequelae, tying this condition family back to Sections 2.1 and 2.2: the beneficiary does not experience four separate conditions but one compounding affordability cascade.</p>
<div class="tbl-wrap" data-reveal>
<table>
<caption><b>Table 1</b> Epidemiology, unit economics, and affordability levers across the four modeled condition families (HSBC-2025; synthetic estimates anchored to published sources<sup>14-18</sup>).</caption>
<thead><tr><th>Condition family</th><th>Modeled prevalence (cohort)</th><th>Annual Rx cost range, list</th><th>Cost-related nonadherence</th><th>Dominant affordability lever</th></tr></thead>
<tbody>
<tr><td>Chronic insomnia</td><td class="num">22.6%</td><td class="num">$60 – $6,100</td><td class="num">18.9% <div class="bar"><i style="--w:19%"></i></div></td><td>Deductible exposure for DORA class; accommodation paperwork burden</td></tr>
<tr><td>Migraine</td><td class="num">14.8%</td><td class="num">$120 – $10,500</td><td class="num">31.4% <div class="bar"><i style="--w:31%"></i></div></td><td>Step-therapy delay to CGRP biologics; site-of-care infusion spreads</td></tr>
<tr><td>Trauma spectrum</td><td class="num">9.7%</td><td class="num">$300 – $8,200</td><td class="num">38.6% <div class="bar"><i style="--w:39%"></i></div></td><td>Visit-limit and network-adequacy gaps in psychotherapy continuity</td></tr>
<tr><td>Postoperative recovery</td><td class="num">11.3% (annual incidence)</td><td class="num">$900 – $28,000 / episode</td><td class="num">24.7% <div class="bar"><i style="--w:25%"></i></div></td><td>Deductible reset per plan year; residual out-of-network ancillary billing</td></tr>
</tbody>
</table>
</div>
<div class="callout" data-tag="Clinical Implication" data-reveal>
<p>Clinicians ordering high-cost agents for these conditions should treat benefit verification as a clinical act, not a clerical one. A CGRP inhibitor prescribed without confirmation of deductible status and step-therapy history has a modeled 31% probability of primary non-fill in the cohort. Embedding benefit investigation into the e-prescribing workflow — with documented fallback regimens — is the single highest-yield intervention available at the point of care.</p>
</div>
</section>
<!-- ================= SECTION 3 ================= -->
<section id="s3">
<div class="sec-head" data-reveal>
<div class="sec-num">03</div>
<div class="sec-title"><small>Section III · Frameworks</small>Socio-Legal & Institutional Frameworks</div>
</div>
<p class="lede" data-reveal>Between the clinician's order and the patient's receipt of care stands a lattice of statutes, regulations, and institutional rules. These frameworks were constructed as civil-rights and labor protections, yet in practice they also function as affordability instruments: they determine who may obtain modified duties, protected leave, medically indicated exemptions, and coverage waivers — and at what documentary price.</p>
<h3 data-reveal><span class="h3-n">3.1</span>ADA Titles I–III: Reasonable Accommodations as Economic Infrastructure</h3>
<p data-reveal>Title I of the ADA obligates covered employers to provide reasonable accommodations to qualified individuals with disabilities through a documented interactive process; Titles II and III extend nondiscrimination and effective-communication obligations to public entities and places of public accommodation, including clinics, pharmacies, and campus health services.<sup>9,21</sup> The affordability relevance is direct. A schedule accommodation granted to a beneficiary with chronic insomnia or migraine can preserve employment-based insurance — the coverage vehicle through which 153 million Americans receive benefits — whereas a denied or delayed accommodation can precipitate the exact coverage gap that converts a manageable condition into a catastrophic bill. Reasonable accommodations under ADA Title II/III in clinical settings (extended appointment windows, low-stimulation environments, environmental sleep hygiene protocols in inpatient units) are low-cost but sit inside the same documentation machinery as costlier employment accommodations. In HSBC-2025, accommodation requests citing migraine and insomnia carried the highest initial-denial rates (22% and 19% respectively), most frequently for insufficient functional-limitation narrative — a documentation quality problem, not a clinical one.</p>
<h3 data-reveal><span class="h3-n">3.2</span>FMLA: Protected Leave Without Protected Income</h3>
<p data-reveal>The Family and Medical Leave Act guarantees up to 12 weeks of unpaid, job-protected leave for eligible employees of covered employers — an eligibility matrix that excludes roughly four in ten US workers through firm-size, tenure, and hours thresholds.<sup>10</sup> For the affordability question, FMLA's structural gap is wage replacement. A postoperative recovery requiring six weeks of leave translates, at the cohort's median wage, into $7,400 of foregone income occurring in the same plan year as deductible reset. The report models this foregone income as an implicit out-of-pocket cost because beneficiaries consistently experience it as such: it competes, dollar for dollar, with pharmacy cost-sharing. The interaction is regressive — lower-wage beneficiaries are both less likely to be FMLA-eligible and less able to absorb the leave-induced income shock, concentrating affordability failure precisely where clinical need is least discretionary.</p>
<h3 data-reveal><span class="h3-n">3.3</span>NCAA Medical Waivers and Roster Compliance</h3>
<p data-reveal>Collegiate athletics constitute a micro-jurisdiction with its own affordability regime. NCAA bylaws governing eligibility, medical hardship waivers (the so-called medical redshirt), and institutional obligations for injury and illness coverage create a setting in which a student-athlete's access to care is conditioned on roster status, scholarship terms, and catastrophic-injury insurance thresholds.<sup>11</sup> Non-permanent functional impairment — concussion sequelae, post-surgical recovery, trauma-associated sleep disturbance — must be documented to a standard sufficient for waiver approval yet restrained enough to protect the athlete's privacy and future insurability. Our modeling of an athletics-department pipeline (Section 4, Figure 4) treated each roster transaction, insurance verification, and waiver submission as a billable administrative event; the median athletics medical-waiver file touched 5.2 distinct offices before final disposition. Trauma-informed clinical waivers for student-athletes with PTSD-spectrum diagnoses present the sharpest tension: the very disclosure required to obtain relief can impair the athlete's position in roster decisions, creating a chilling effect we quantify in Section 5.</p>
<h3 data-reveal><span class="h3-n">3.4</span>Employer Health Waivers, Opt-Outs, and Wellness Carve-Outs</h3>
<p data-reveal>Employers increasingly deploy coverage waivers and opt-out incentives — cash payments for declining employer coverage, spousal surcharges, and wellness-program premium differentials under the ACA/HIPAA incentive rules — as cost-containment instruments. Modeled naively, these are actuarially sound; modeled behaviorally, they sort risk. Higher-income, lower-morbidity employees take the opt-out cash; higher-morbidity employees retain coverage and absorb the surcharges. The HSBC-2025 simulation found that a representative $1,200 opt-out incentive shifted 6.8% of the healthy-risk segment off-plan while raising the residual pool's average claims cost by 3.1% — a cross-subsidy reversal that eventually reprices premiums for exactly the beneficiaries with the chronic conditions in Section 2. Wellness carve-outs for biometric screening likewise penalize beneficiaries whose GLP-1 or metabolic regimens are mid-titration, converting a clinical transition into a premium event.</p>
<h3 data-reveal><span class="h3-n">3.5</span>The Inflation Reduction Act and Price Transparency: The Regulatory Counterweight</h3>
<p data-reveal>Two federal instruments define the forward policy environment. The Inflation Reduction Act's Medicare Drug Price Negotiation Program selected ten drugs for initial negotiation (effective 2026) and fifteen for the second round, with maximum fair prices ranging from 25% to 79% below list; obesity and diabetes agents remain outside Part D negotiation eligibility for now, but the pipeline pressure on GLP-1 pricing strategy is unmistakable.<sup>3,4</sup> Concurrently, hospital and insurer price-transparency rules require machine-readable files of gross and negotiated charges and consumer-facing displays of shoppable services; compliance audits continue to find material noncompliance and unusable files, which Section 4 quantifies. Together these instruments attack the price layer directly — while Sections 3.1 through 3.4 show that the administrative layer will capture much of the benefit unless managed deliberately.</p>
<div class="tbl-wrap" data-reveal>
<table>
<caption><b>Table 2</b> Statute-to-mechanism map: how each framework mediates affordability and the documentation risk it imposes.</caption>
<thead><tr><th>Framework</th><th>Covered population</th><th>Affordability mechanism</th><th>Documentation risk profile</th></tr></thead>
<tbody>
<tr><td>ADA Title I</td><td>Qualified employees w/ disability</td><td>Reasonable accommodations preserve employment-based coverage</td><td>Functional-limitation narrative; interactive-process records discoverable in litigation</td></tr>
<tr><td>ADA Title II/III</td><td>Patients in public entities & public accommodations</td><td>Effective communication & modified clinical environments</td><td>Low clinical risk; inconsistent intake capture</td></tr>
<tr><td>FMLA (29 USC §2601)</td><td>Eligible employees, covered employers</td><td>Job-protected but unpaid leave; implicit OOP via lost wages<sup>10</sup></td><td>Certification/recertification cycles; employer notice defects</td></tr>
<tr><td>NCAA Bylaws 14 & 16</td><td>Student-athletes</td><td>Medical hardship waivers; catastrophic insurance requirements<sup>11</sup></td><td>High — roster, scholarship & future insurability exposure</td></tr>
<tr><td>ACA/HIPAA wellness rules</td><td>Group health enrollees</td><td>Premium differentials & coverage opt-outs</td><td>Risk-sorting; biometric data handling</td></tr>
<tr><td>IRA §11001 (Medicare negotiation)</td><td>Medicare beneficiaries</td><td>Maximum fair prices, 2026– effective<sup>3,4</sup></td><td>Manufacturer data submission; patent/eligibility disputes</td></tr>
<tr><td>Transparency rules (45 CFR 180/171)</td><td>All payers & hospitals</td><td>Published gross/negotiated rates; good-faith estimates for uninsured</td><td>File validity; enforcement lag</td></tr>
</tbody>
</table>
</div>
<div class="callout" data-tag="Regulatory Note" data-reveal>
<p>None of these frameworks contains an affordability mandate. Each protects a right — to accommodation, to leave, to eligibility relief, to information. The Havellum analysis treats the gap between protected rights and financed access as the operative policy failure: institutions can be fully compliant with every statute above while their beneficiaries still cannot afford the drugs those statutes were meant to make reachable.</p>
</div>
</section>
<!-- ================= SECTION 4 ================= -->
<section id="s4">
<div class="sec-head" data-reveal>
<div class="sec-num">04</div>
<div class="sec-title"><small>Section IV · Results</small>Empirical Analysis & Data Visualizations</div>
</div>
<p class="lede" data-reveal>All figures below derive from the HSBC-2025 microsimulation and are synthetic estimates calibrated to public benchmarks; they are presented as modeled results, not as claims data. Six interactive visualizations decompose the cost-sharing cascade, the coverage-decision trade space, the exemption pipeline, the multidimensional burden profile, the premium trend, and the policy roadmap.</p>
<h4 data-reveal>Methods (4.0)</h4>
<p data-reveal>The cohort was generated by Monte-Carlo assignment of condition states (Section 2 prevalences, including 27% multimorbidity overlap), payer mix (61% commercial employer-sponsored, 18% Medicare-eligible, 12% Medicaid dual-eligible pathways, 9% individual market), and benefit designs drawn from 2024 KFF distributions (HDHP enrollment 29%, median single deductible $1,787).<sup>1,22</sup> Drug prices were applied at WAC and netted against published rebate ranges for each class.<sup>5,6,16</sup> Administrative events (prior authorizations, appeals, exemption filings, roster transactions) were costed at fully loaded staff time. All dollar figures are FY2024 dollars. Chart libraries render client-side; figures are interactive on hover.</p>
<figure class="chart-card" data-reveal id="fig1wrap">
<div class="fc-head"><span class="fc-tag">Figure 1 · Cost Cascade</span><span class="fc-title">Annual Out-of-Pocket Waterfall — Triple-Therapy Beneficiary (GLP-1 RA + CGRP mAb + DORA)</span></div>
<div class="canvas-wrap"><canvas id="fig1" role="img" aria-label="Waterfall chart of patient out-of-pocket cost accumulation"></canvas></div>
<figcaption><b>Reading the cascade:</b> Bars ascending from the running total are additive patient liabilities; recessed bars are protections (No Surprises Act adjustment, out-of-pocket maximum). Without the OOP maximum, modeled liability would reach $7,950; the cap converts $2,000 of exposure into plan-paid cost, yielding a realized median liability of $5,950 — 8.4% of median cohort household income.</figcaption>
</figure>
<p data-reveal>The waterfall exposes the central design flaw of HDHP-era benefits: the protections exist, but they engage only after the beneficiary has already financed the peak of exposure. The GLP-1 coinsurance segment alone ($2,980) exceeds the median deductible, meaning that for beneficiaries early in their plan year, the first specialty fill is predominantly patient-financed. Copay-accumulator programs further erode the apparent protection: manufacturer assistance that would have offset the CGRP segment is counted toward the accumulator but, in roughly one-third of modeled plans, not toward the true out-of-pocket maximum, deferring catastrophic relief by an average of 2.3 months.</p>
<figure class="chart-card" data-reveal>
<div class="fc-head"><span class="fc-tag">Figure 2 · Decision Matrix</span><span class="fc-title">Coverage Priority 2×2 — Clinical Benefit vs Budget Impact per 1,000 Covered Lives</span></div>
<div class="canvas-wrap tall"><canvas id="fig2" role="img" aria-label="Bubble chart of coverage decisions by benefit and budget impact"></canvas></div>
<div class="quad-legend">
<span>Cover & simplify (low budget / high benefit)</span>
<span>Manage with structured criteria (high / high)</span>
<span>Cover & monitor (low / low)</span>
<span>Restrict or exclude (high budget / low benefit)</span>
</div>
<figcaption><b>Quadrant logic:</b> Bubble area scales with condition prevalence per 1,000 lives. GLP-1 therapy for obesity occupies the contested northeast quadrant — high modeled benefit (SELECT/STEP-class evidence<sup>7</sup>) against the cohort's largest budget impact — while buprenorphine and insulin analogs anchor the "cover and simplify" quadrant, where administrative controls impose net harm.<sup>8</sup></figcaption>
</figure>
<p data-reveal>The matrix is offered as a formulary-governance instrument rather than a verdict. The cohort simulation shows that when northeast-quadrant agents are managed with blunt exclusion, total cost of care rises within 18 months as downstream events (surgical episodes, cardiovascular admissions) migrate back onto the plan. Conversely, lower-left agents subjected to step therapy generate pure friction cost with no budget offset. The recommendation implicit in Figure 2 — and made explicit in Section 6 — is tiered administrative intensity proportional to quadrant, not to drug class tradition.</p>
<figure class="chart-card" data-reveal>
<div class="fc-head"><span class="fc-tag">Figure 3 · Approval Funnel</span><span class="fc-title">Exemption & Waiver Pipeline — From Filed Request to Sustained Approval (n = 12,480 filings)</span></div>
<div class="canvas-wrap tall"><canvas id="fig3" role="img" aria-label="Funnel diagram of exemption approval progression"></canvas></div>
<figcaption><b>Pipeline attrition:</b> 42.0% of filed medically indicated exemptions fail to reach sustained approval at 12 months. The largest single loss occurs between complete documentation and clinical review — 1,470 cases stalled by reviewer availability — a resourcing failure rather than a clinical one. Trauma-informed waiver requests lose a further 9 points of conversion relative to the pipeline mean.</figcaption>
</figure>
<p data-reveal>The funnel is the administrative layer made visible. Each stage imposes its own documentation grammar: ADA filings require functional-limitation narratives, FMLA certifications require provider completion of federal forms, NCAA medical waivers require roster-corroborated impairment timelines, and employer waivers require benefits-committee packets. The simulation attributes the stage-two attrition to a median 17-day gap between documentation completion and reviewer assignment; compressing that gap to five days recovers an estimated 1,100 approvals per 12,480 filings — the highest-leverage single fix identified anywhere in this report.</p>
<figure class="chart-card" data-reveal>
<div class="fc-head"><span class="fc-tag">Figure 4 · Burden Profile</span><span class="fc-title">Multidimensional Condition Burden — Six-Axis Radar (0–10 composite scores)</span></div>
<div class="canvas-wrap tall"><canvas id="fig4" role="img" aria-label="Radar chart comparing burden dimensions across four condition families"></canvas></div>
<figcaption><b>Interpretation:</b> Axis scores are cohort composites of validated instruments and modeled economic measures. Trauma-spectrum illness leads on administrative burden; postoperative recovery leads on pain and treatment-cost intensity; insomnia leads on sleep disruption with paradoxically low treatment-cost intensity — the profile most likely to be dismissed by benefit design.</figcaption>
</figure>
<figure class="chart-card" data-reveal>
<div class="fc-head"><span class="fc-tag">Figure 5 · Trend Analysis</span><span class="fc-title">Employer Premium & Deductible Growth, FY2015–FY2025 (KFF benchmarks + Havellum projection)</span></div>
<div class="canvas-wrap"><canvas id="fig5" role="img" aria-label="Line chart of premium growth 2015 to 2025"></canvas></div>
<figcaption><b>Trend:</b> Single premiums rose ≈50% and family premiums ≈53% over the decade; median HDHP deductibles rose faster than wages in eight of eleven years. The FY2025 points are Havellum projections from a 5.1% trend-line premium growth assumption.<sup>1,22</sup></figcaption>
</figure>
<p data-reveal>The trend figure establishes the denominator problem: every affordability intervention measured in this report operates against a base that is itself compounding at roughly 5% annually. Benefit redesign that merely shifts cost-sharing therefore loses ground; only interventions that attack the numerator (net price, administrative cost, episode design) can outpace the trend.</p>
<figure class="chart-card" data-reveal>
<div class="fc-head"><span class="fc-tag">Figure 6 · Policy Roadmap</span><span class="fc-title">Implementation Timeline — Regulatory, Payer, and Institutional Initiatives, Q1 2025 – Q3 2028</span></div>
<div class="canvas-wrap tall"><canvas id="fig6" role="img" aria-label="Gantt chart of policy implementation milestones"></canvas></div>
<figcaption><b>Sequencing:</b> Bars denote modeled implementation windows by actor class. Milestone markers indicate the IRA round-one effective date (Q1 2026) and the modeled round-two price-setting date (Q3 2027). Institutional navigation programs are front-loaded because they deliver benefit inside the current regime rather than awaiting it.<sup>3,4</sup></figcaption>
</figure>
<div class="tbl-wrap" data-reveal>
<table>
<caption><b>Table 3</b> Exemption pipeline stage detail — counts, conversion, cycle time, and dominant attrition driver (HSBC-2025).</caption>
<thead><tr><th>Pipeline stage</th><th>n</th><th>Stage conversion</th><th>Median cycle time</th><th>Dominant attrition driver</th></tr></thead>
<tbody>
<tr><td>Request filed</td><td class="num">12,480</td><td class="num">—</td><td class="num">Day 0</td><td>—</td></tr>
<tr><td>Documentation complete</td><td class="num">10,110</td><td class="num">81.0%</td><td class="num">Day 9</td><td>Patient & provider documentation latency</td></tr>
<tr><td>Clinical review initiated</td><td class="num">8,640</td><td class="num">85.5%</td><td class="num">Day 26</td><td>Reviewer availability gap (17 d median)</td></tr>
<tr><td>Interim accommodation granted</td><td class="num">6,905</td><td class="num">79.9%</td><td class="num">Day 34</td><td>Insufficient functional-limitation narrative</td></tr>
<tr><td>Final approval sustained (12 mo)</td><td class="num">5,236</td><td class="num">75.8%</td><td class="num">Day 58</td><td>Renewal re-documentation burden; FMLA recertification</td></tr>
</tbody>
</table>
</div>
<div class="tbl-wrap" data-reveal>
<table>
<caption><b>Table 4</b> GLP-1 RA coverage posture by payer archetype — modeled median patient economics and utilization controls.</caption>
<thead><tr><th>Payer archetype</th><th>Obesity-indication coverage</th><th>T2D-indication coverage</th><th>Typical utilization controls</th><th>Median patient OOP / mo</th></tr></thead>
<tbody>
<tr><td>Commercial, fully insured</td><td>In ~38% of modeled plans</td><td>Standard</td><td>PA w/ BMI + comorbidity criteria; 6-wk reassessment</td><td class="num">$75 – $425</td></tr>
<tr><td>Self-funded employer</td><td>Highly variable; carve-outs common</td><td>Standard</td><td>Step therapy; accumulator programs; outcome contracts</td><td class="num">$95 – $1,060</td></tr>
<tr><td>Medicare Part D</td><td>Statutorily excluded (obesity)</td><td>Standard, negotiation-eligible agents pending<sup>4</sup></td><td>Formulary tiering; 2025 redesign cap $2,000/yr</td><td class="num">$0 – $167</td></tr>
<tr><td>Medicaid (expansion states)</td><td>State-preference dependent</td><td>Standard</td><td>Preferring agencies; rebate-driven formulary</td><td class="num">$0 – $8</td></tr>
</tbody>
</table>
</div>
<div class="callout" data-tag="Methodological Disclosure" data-reveal>
<p>HSBC-2025 is a synthetic cohort. No individual patient, claim, or institution is represented. Calibration anchors are cited in Section 7; sensitivity analysis (±15% on WAC, ±2 points on HDHP share) leaves headline conclusions invariant while moving point estimates within the ranges shown. Havellum publishes the parameter tables on request for academic replication.</p>
</div>
</section>
<!-- ================= SECTION 5 ================= -->
<section id="s5">
<div class="sec-head" data-reveal>
<div class="sec-num">05</div>
<div class="sec-title"><small>Section V · Ethics & Governance</small>Ethical, Privacy, and Administrative Conflict Resolution</div>
</div>
<p class="lede" data-reveal>Every affordability mechanism described above is also a data mechanism. Exemption files, waiver packets, roster transactions, and utilization-management records create parallel dossiers whose governance determines whether patients trust — and therefore use — the protections on paper.</p>
<h3 data-reveal><span class="h3-n">5.1</span>HIPAA Minimum Necessary and the Employer-Documentation Conflict</h3>
<p data-reveal>The HIPAA Privacy Rule's minimum-necessary standard collides with the documentation appetites of accommodation and waiver processes.<sup>12</sup> Employers and institutions frequently request complete clinical records when a functional-limitation summary would satisfy the legal standard; athletic departments request diagnostic specificity when impairment timelines would suffice. The report documents three recurring conflict patterns: (1) group health plan claims data being informally visible to benefits administrators adjudicating waivers — a clear segregation failure under 45 CFR 164; (2) FMLA certifications routed through line managers rather than designated leave administrators; and (3) student-athlete treatment records flowing into roster-decision meetings without FERPA/HIPAA-conformant redaction. Each pattern is legally hazardous and, more importantly, behaviorally corrosive: the cohort modeled a 12-point reduction in waiver-filing propensity among beneficiaries who had previously experienced a disclosure breach — suppressed demand that never appears in any denial statistic.</p>
<h3 data-reveal><span class="h3-n">5.2</span>Prior Authorization Ethics and Algorithmic Utilization Management</h3>
<p data-reveal>Prior authorization for northeast-quadrant agents (Figure 2) is defensible when criteria are published, decisions are timely, and denials are reviewable. The cohort found all three conditions violated with measurable frequency: criteria unpublished in 24% of modeled plan documents, decision times exceeding statutory or contractual windows in 18% of cases, and denial letters lacking adequate reasoning in 31%. The introduction of algorithmic pre-screening into PA workflows raises a further duty: institutions deploying predictive denial tools should treat them as clinical decision interventions, subject to the same validation and appeal rights as the decisions they automate. Peer-to-peer review remains the most underused de-escalation instrument — invoked in only 14% of modeled CGRP denials despite reversing roughly half when used.</p>
<h3 data-reveal><span class="h3-n">5.3</span>A Structured Conflict-Resolution Ladder</h3>
<p data-reveal>The report proposes a five-rung ladder, mirrored from ERISA claims procedures, state independent-review organization (IRO) statutes, and No Surprises Act dispute resolution:<sup>13</sup> (1) internal redetermination within 7 days; (2) peer-to-peer clinical review; (3) external IRO review at plan expense; (4) expedited arbitration for time-sensitive therapies, with interim supply coverage during dispute; and (5) transparency of outcomes — institutions should publish aggregate approval, denial, and reversal rates by drug class and condition family. Publication is the rung most often omitted and the one that disciplines all the others. Rostering conflicts in athletics should follow the same ladder with an added privacy rung: no roster transaction may be conditioned on disclosure beyond the impairment timeline required by the waiver standard.</p>
<div class="callout dark" data-tag="Ethical Position" data-reveal>
<p>The deepest ethical finding is suppression, not denial. Systems measure the requests they refuse and ignore the requests never filed. Trauma-informed populations, student-athletes, and shift workers under-file because the documentation process itself carries social and professional risk. An affordability framework that counts only adjudicated cases systematically overstates access. Havellum recommends institutions survey non-filers annually and treat suppressed demand as a reportable quality metric.</p>
</div>
</section>
<!-- ================= SECTION 6 ================= -->
<section id="s6">
<div class="sec-head" data-reveal>
<div class="sec-num">06</div>
<div class="sec-title"><small>Section VI · Strategy</small>Strategic Recommendations for Health Systems & Academic Institutions</div>
</div>
<p class="lede" data-reveal>Ten recommendations follow, grouped by actor. Each is sequenced to deliver benefit within the current regulatory regime rather than awaiting the 2026–2028 changes mapped in Figure 6, and each is traceable to a specific finding in Sections 4 and 5.</p>
<div class="rec" data-reveal><div class="r-n">R1</div><div><span class="r-scope">Health Systems</span><h5>Stand up an affordability navigation service inside the revenue cycle</h5><p>Assign every high-cost initiation (GLP-1 RA, CGRP agent, DORA, biologic) a benefit investigation before first fill, with documented fallback regimens and manufacturer-assistance routing. Modeled effect: 22-point reduction in primary non-fill.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R2</div><div><span class="r-scope">Health Systems</span><h5>Publish usable prices, not merely compliant files</h5><p>Go beyond machine-readable transparency files to consumer-facing episode estimates (surgical episodes, infusion courses) with good-faith estimate workflows for uninsured and self-pay patients. Compliance alone leaves the cohort's shoppable-services utilization below 4%.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R3</div><div><span class="r-scope">Health Systems</span><h5>Compress the reviewer-availability gap in exemption pipelines</h5><p>The 17-day stage-two gap (Table 3) is the single highest-leverage fix: pooled cross-trained reviewers and same-week triage recover ≈1,100 approvals per 12,480 filings without changing any clinical criterion.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R4</div><div><span class="r-scope">Employers</span><h5>Tier administrative intensity by quadrant, not by class tradition</h5><p>Apply structured criteria to northeast-quadrant agents (Figure 2), eliminate step therapy for lower-left agents where it generates pure friction, and sunset copay accumulators in favor of true out-of-pocket crediting.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R5</div><div><span class="r-scope">Employers</span><h5>Audit opt-out and wellness designs for risk sorting</h5><p>Model every coverage waiver and biometric differential against adverse-selection before adoption; cap wellness differentials and exempt beneficiaries mid-titration on metabolic regimens from biometric penalties.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R6</div><div><span class="r-scope">Employers</span><h5>Pair FMLA with wage-replacement bridges for surgical episodes</h5><p>Because foregone leave income is an implicit out-of-pocket cost competing with pharmacy cost-sharing, short-term disability bridges targeted at deductible-reset quarters materially improve postoperative adherence in the model.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R7</div><div><span class="r-scope">Academic Institutions</span><h5>Adopt an NCAA-aligned athletics medical-waiver standard with privacy rungs</h5><p>Waiver files should require impairment timelines, not diagnoses; roster transactions must never be conditioned on disclosure beyond the waiver standard, and catastrophic-insurance verification should be automated at enrollment.<sup>11</sup></p></div></div>
<div class="rec" data-reveal><div class="r-n">R8</div><div><span class="r-scope">Academic Institutions</span><h5>Deploy trauma-informed clinical waivers with reduced re-documentation</h5><p>One verified waiver should carry across semesters absent material change; the modeled 41-day trauma-waiver cycle and its chilling effect on filing justify presumptive renewal.</p></div></div>
<div class="rec" data-reveal><div class="r-n">R9</div><div><span class="r-scope">Policymakers</span><h5>Enforce transparency usability and publish PA outcome statistics</h5><p>Require payers to publish approval, denial, and reversal rates by class and condition family; penalize unusable transparency files; and extend No Surprises protections to post-acute ancillary settings where modeled exposure persists.<sup>13</sup></p></div></div>
<div class="rec" data-reveal><div class="r-n">R10</div><div><span class="r-scope">All Actors</span><h5>Measure suppressed demand, not only adjudicated denials</h5><p>Annual anonymous surveys of non-filers and abandoned carts convert invisible access failure into a reportable metric — the precondition for governing it.</p></div></div>
<div class="duo" data-reveal>
<img src="https://picsum.photos/seed/academic-medical-center-corridor/1600/460" alt="Illustrative academic medical center corridor" loading="lazy">
<div class="duo-cap">Illustrative — Academic Medical Center Implementation Context</div>
</div>
</section>
<!-- ================= SECTION 7 ================= -->
<section id="s7">
<div class="sec-head" data-reveal>
<div class="sec-num">07</div>
<div class="sec-title"><small>Section VII · Close</small>Conclusion & References</div>
</div>
<p class="lede" data-reveal>The evidence assembled here supports a blunt conclusion: Americans can afford their health system less each year not because medicine stopped working, but because the financing architecture has been quietly re-engineered to transfer price risk downward while leaving administrative complexity upward. The GLP-1 controversy is the most visible symptom, not the disease. The disease is the coupling — list price, benefit design, and documentation friction acting as one mechanism against patients who experience insomnia, migraine, trauma, and surgical recovery as a single life.</p>
<p data-reveal>The counterweight is equally systemic. The Inflation Reduction Act's negotiation program, transparency enforcement, and the Part D redesign attack the price layer directly; the recommendations in Section 6 attack the administrative layer at points of maximal leverage; and the privacy discipline in Section 5 protects the trust without which neither layer functions. Institutions that treat affordability as a quality metric — published, tracked, and owned at the executive level — will outperform those that treat it as a billing artifact. That is the Havellum position, and it is the standard by which we will score the FY2026–FY2028 policy window mapped in Figure 6.</p>
<p data-reveal>We close with the obligation of any modeled analysis: these are synthetic estimates, calibrated and disclosed, intended to structure decisions rather than replace them. The patients behind the cohort's distributions are real. The prices are real. The paperwork is real. Affordability is a design choice, and it is being made — by default, every day, in every formulary meeting, waiver packet, and deductible schedule in the country. It should be made deliberately.</p>
<h4 data-reveal>References (AMA Style)</h4>
<ol class="refs" data-reveal>
<li>Claxton G, Rae M, Damico A, et al. <em>Health Benefits in 2024.</em> KFF Employer Health Benefits Survey. KFF; 2024.</li>
<li>Centers for Medicare & Medicaid Services. National Health Expenditure data, 2023. CMS website. Updated December 2024.</li>
<li>Inflation Reduction Act of 2022, Pub L No 117-169, §11001, 136 Stat 1818 (2022) (codified as amended at 42 USC §1320f).</li>
<li>Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: initial selected drugs and second-round selection. CMS fact series; 2023–2024.</li>
<li>US Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. FDA; revised 2024.</li>
<li>US Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. FDA; 2023.</li>
<li>Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). <em>N Engl J Med.</em> 2021;384(11):989-1002.</li>
<li>Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). <em>N Engl J Med.</em> 2022;387(4):327-340.</li>
<li>ADA National Network. Americans with Disabilities Act: Title I (employment), Title II (public entities), Title III (public accommodations). ADANetwork.org; 2023.</li>
<li>Family and Medical Leave Act of 1993, 29 USC §2601 et seq.</li>
<li>National Collegiate Athletic Association. <em>2024-25 NCAA Division I Manual: Bylaws 14 (eligibility) and 16 (student-athlete benefits).</em> NCAA; 2024.</li>
<li>Standards for privacy of individually identifiable health information (HIPAA Privacy Rule), 45 CFR pt 164.</li>
<li>No Surprises Act, div BB of the Consolidated Appropriations Act, 2021, Pub L No 116-260, 134 Stat 2863 (2020).</li>
<li>Roth T. Insomnia: definition, prevalence, epidemiology, and differential diagnosis. <em>Sleep.</em> 2007;30(suppl):S3-S5.</li>
<li>GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries, 1990–2019. <em>Lancet.</em> 2020;396(10258):1204-1222.</li>
<li>Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. <em>Lancet.</em> 2021;397(10285):1603-1618.</li>
<li>Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. <em>J Trauma Stress.</em> 2013;26(5):537-547.</li>
<li>Memtsoudis SG, Cozowicz C, Bekeris J, et al. Enhanced recovery after surgery components and perioperative outcomes: a nationwide observational study. <em>Br J Anaesth.</em> 2019;122(5):638-647.</li>
<li>Cutler DM, Feldman NE, Horwitz JR. The costs of administrative complexity in the US health system. <em>Health Aff (Millwood).</em> 2024;43(5):613-621.</li>
<li>Bai G, Anderson GF. A more detailed understanding of spending and prices for branded prescription drugs. <em>Health Aff (Millwood).</em> 2021;40(9):1389-1397.</li>
<li>Americans with Disabilities Act of 1990, as amended, 42 USC §12101 et seq.</li>
<li>Claxton G, Rae M, McDermott D, Damico A. Employee cost sharing in employer health plans: deductibles and out-of-pocket limits. KFF issue brief; 2024.</li>
</ol>
</main>
</div>
<!-- ============ FOOTER ============ -->
<footer>
<div class="foot-inner">
<div>
<div class="foot-word">Have<em>llum</em></div>
<p>Institute for Health Policy & Clinical Economics. Independent, non-commercial analysis at the intersection of clinical evidence, benefit design, and health law. Report HV-2025-07 was prepared under AMA Manual of Style (11th ed.) conventions.</p>
</div>
<div>
<h5>Data & Modeling Disclosure</h5>
<ul>
<li>HSBC-2025 is a synthetic cohort; no real patient or claim data appear.</li>
<li>Benchmarks: KFF, CMS, FDA labeling, IRA program publications.</li>
<li>All WAC figures are list prices; net prices vary by contract.</li>
</ul>
</div>
<div>
<h5>Report Navigation</h5>
<ul>
<li><a href="#s1" style="color:rgba(255,255,255,.8)">Executive Overview</a></li>
<li><a href="#s4" style="color:rgba(255,255,255,.8)">Empirical Analysis & Figures</a></li>
<li><a href="#s6" style="color:rgba(255,255,255,.8)">Strategic Recommendations</a></li>
<li><a href="#s7" style="color:rgba(255,255,255,.8)">References</a></li>
</ul>
</div>
</div>
<div class="foot-base">
<span>© 2025 Havellum Institute for Health Policy & Clinical Economics</span>
<span>HV-2025-07 · Peer-Review Draft 4.2 · AMA Style Compliant</span>
</div>
</footer>
<script>
(function(){
"use strict";
var reduced = window.matchMedia("(prefers-reduced-motion: reduce)").matches;
/* ---------- ticker ---------- */
var items = [
["WEGOVY 2.4 MG","WAC $1,349.02/MO"],["ZEPBOUND 15 MG","WAC $1,059.87/MO"],
["OZEMPIC 2 MG","WAC $968.52/MO"],["AIMOVIG 70 MG","WAC ≈$597/MO"],
["DAYVIGO 10 MG","WAC ≈$507/MO"],["LECANEMAB","WAC $26,500/YR"],
["INSULIN LISPRO","MEDICARE CAP $35/MO"],["SINGLE PREMIUM 2024","AVG $8,951 ▲6.2%"],
["FAMILY PREMIUM 2024","AVG $25,570 ▲7.0%"],["HDHP DEDUCTIBLE","AVG $1,787/SINGLE"],
["IRA ROUND 1","10 DRUGS · EFFECTIVE 2026"],["IRA ROUND 2","15 DRUGS SELECTED"]
];
var track = document.getElementById("tickerTrack");
if(track){
var html = items.map(function(i){return "<span><i>"+i[0]+"</i><b>"+i[1]+"</b></span>";}).join("");
track.innerHTML = html + html; /* seamless loop */
}
/* ---------- progress bar ---------- */
var prog = document.getElementById("progress");
function onScroll(){
var h = document.documentElement;
var pct = h.scrollTop / (h.scrollHeight - h.clientHeight) * 100;
prog.style.width = pct + "%";
}
window.addEventListener("scroll", onScroll, {passive:true}); onScroll();
/* ---------- reveal ---------- */
var revealEls = document.querySelectorAll("[data-reveal]");
if(reduced || !("IntersectionObserver" in window)){
revealEls.forEach(function(e){e.classList.add("in");});
}else{
var io = new IntersectionObserver(function(entries){
entries.forEach(function(en){
if(en.isIntersecting){
var d = en.target.getAttribute("data-delay");
if(d) en.target.style.transitionDelay = d + "ms";
en.target.classList.add("in");
io.unobserve(en.target);
}
});
},{threshold:.12});
revealEls.forEach(function(e){io.observe(e);});
}
/* ---------- count-up KPIs ---------- */
function fmt(v,dec,prefix,suffix){
return (prefix||"") + v.toLocaleString("en-US",{minimumFractionDigits:dec,maximumFractionDigits:dec}) + (suffix||"");
}
var counters = document.querySelectorAll("[data-count]");
function runCount(el){
var target = parseFloat(el.getAttribute("data-count")),
dec = parseInt(el.getAttribute("data-decimals")||"0",10),
pre = el.getAttribute("data-prefix")||"", suf = el.getAttribute("data-suffix")||"";
if(reduced){ el.textContent = fmt(target,dec,pre,suf); return; }
var t0 = null, dur = 1400;
function step(ts){
if(!t0) t0 = ts;
var p = Math.min((ts-t0)/dur,1), e = 1-Math.pow(1-p,3);
el.textContent = fmt(target*e,dec,pre,suf);
if(p<1) requestAnimationFrame(step); else el.textContent = fmt(target,dec,pre,suf);
}
requestAnimationFrame(step);
}
if("IntersectionObserver" in window){
var cio = new IntersectionObserver(function(entries){
entries.forEach(function(en){ if(en.isIntersecting){ runCount(en.target); cio.unobserve(en.target);} });
},{threshold:.4});
counters.forEach(function(c){cio.observe(c);});
}else counters.forEach(runCount);
/* ---------- scroll spy ---------- */
var links = document.querySelectorAll(".toc a");
var secs = [];
links.forEach(function(a){ var id=a.getAttribute("href").slice(1), s=document.getElementById(id); if(s) secs.push([s,a]); });
if("IntersectionObserver" in window){
var sio = new IntersectionObserver(function(entries){
entries.forEach(function(en){
if(en.isIntersecting){
links.forEach(function(l){l.classList.remove("active");});
var pair = secs.find(function(p){return p[0]===en.target;});
if(pair) pair[1].classList.add("active");
}
});
},{rootMargin:"-35% 0px -55% 0px"});
secs.forEach(function(p){sio.observe(p[0]);});
}
/* ---------- charts ---------- */
if(typeof Chart === "undefined") return;
if(reduced) Chart.defaults.animation = false;
Chart.defaults.font.family = "'Inter', system-ui, sans-serif";
Chart.defaults.color = "#111827";
Chart.defaults.borderColor = "rgba(17,24,39,.10)";
var NAVY="#1e3a8a", INK="#111827", N80="rgba(30,58,138,.8)", N55="rgba(30,58,138,.55)",
N35="rgba(30,58,138,.35)", N18="rgba(30,58,138,.18)";
var money = function(v){ return "$" + Math.round(v).toLocaleString("en-US"); };
var made = {};
function build(name){
if(made[name] || !document.getElementById(name)) return; made[name]=true;
switch(name){
case "fig1": waterfall(); break;
case "fig2": bubble(); break;
case "fig3": funnel(); break;
case "fig4": radar(); break;
case "fig5": trend(); break;
case "fig6": gantt(); break;
}
}
/* --- Fig 1: Waterfall --- */
function waterfall(){
var steps = [
{l:"GLP-1 RA coinsurance & deductible", v: 2980},
{l:"CGRP mAb patient cost share", v: 1240},
{l:"DORA copays (insomnia)", v: 620},
{l:"Diagnostics, labs & imaging", v: 480},
{l:"Out-of-network anesthesia billing", v: 760},
{l:"No Surprises Act adjustment", v: -310},
{l:"Telehealth & follow-up visits", v: 180},
{l:"Subtotal, pre-protection", v: null, total:true},
{l:"Out-of-pocket maximum relief", v: -2000},
{l:"Patient realized liability", v: null, final:true}
];
var cum=0, data=[], colors=[], labels=[];
steps.forEach(function(s){
labels.push(s.l);
if(s.total){ data.push([0,cum]); colors.push(INK); }
else if(s.final){ data.push([0,cum]); colors.push(NAVY); }
else if(s.v>=0){ data.push([cum,cum+s.v]); cum+=s.v; colors.push(NAVY); }
else { data.push([cum+s.v,cum]); cum+=s.v; colors.push(N35); }
});
new Chart(document.getElementById("fig1"),{
type:"bar",
data:{labels:labels,datasets:[{data:data,backgroundColor:colors,borderColor:colors,borderWidth:1,borderSkipped:false,barPercentage:.66,categoryPercentage:.9}]},
options:{responsive:true,maintainAspectRatio:false,
plugins:{legend:{display:false},
tooltip:{backgroundColor:INK,titleFont:{family:"'Merriweather',serif",size:12},bodyFont:{size:12},padding:12,
callbacks:{label:function(c){var d=c.raw; return " " + money(d[1]-d[0]);}}}},
scales:{
x:{grid:{display:false},ticks:{font:{size:10},maxRotation:40,minRotation:40}},
y:{beginAtZero:true,grid:{color:"rgba(17,24,39,.08)"},ticks:{callback:function(v){return "$"+(v/1000)+"k";}}}
}},
plugins:[{id:"wl",afterDatasetsDraw:function(ch){
var ctx=ch.ctx; ctx.save(); ctx.font="600 10.5px Inter"; ctx.textAlign="center";
ch.getDatasetMeta(0).data.forEach(function(bar,i){
var d=ch.data.datasets[0].data[i]; ctx.fillStyle = (d[1]-d[0]>=0 && ch.data.datasets[0].backgroundColor[i]!==N35)? INK : INK;
ctx.fillStyle="#111827";
ctx.fillText((ch.data.datasets[0].data[i][1]-ch.data.datasets[0].data[i][0]>=0?"+":"−")+money(Math.abs(ch.data.datasets[0].data[i][1]-ch.data.datasets[0].data[i][0])), bar.x, bar.y-6);
}); ctx.restore();
}}]
});
}
/* --- Fig 2: 2x2 bubble matrix --- */
function bubble(){
var pts=[
{x:340,y:7.6,r:26,l:"GLP-1 RA (obesity)"},
{x:180,y:8.4,r:16,l:"GLP-1 RA (T2D)"},
{x:95, y:7.1,r:11,l:"CGRP mAbs"},
{x:70, y:6.4,r:9, l:"Gepants (oral)"},
{x:55, y:5.6,r:13,l:"DORA class"},
{x:150,y:4.2,r:6, l:"Lecanemab"},
{x:60, y:8.8,r:18,l:"Insulin analogs"},
{x:18, y:8.9,r:10,l:"Buprenorphine"},
{x:10, y:3.8,r:12,l:"Donepezil"}
];
new Chart(document.getElementById("fig2"),{
type:"bubble",
data:{datasets:[{
data:pts, backgroundColor:pts.map(function(p,i){return i===0?N80: i===5?N35: i>=7?"rgba(17,24,39,.55)":N55;}),
borderColor:NAVY, borderWidth:1.2
}]},
options:{responsive:true,maintainAspectRatio:false,
plugins:{legend:{display:false},
tooltip:{backgroundColor:INK,padding:12,callbacks:{
label:function(c){var p=pts[c.dataIndex]; return " "+p.l+" — benefit "+p.y+"/10 · budget $"+p.x+"K/1k lives";}}}},
scales:{
x:{min:0,max:400,title:{display:true,text:"Annual budget impact per 1,000 covered lives ($K)",font:{size:11}},grid:{color:"rgba(17,24,39,.07)"}},
y:{min:0,max:10,title:{display:true,text:"Composite clinical benefit (0–10)",font:{size:11}},grid:{color:"rgba(17,24,39,.07)"}}
}},
plugins:[{id:"quad",afterDraw:function(ch){
var a=ch.chartArea, ctx=ch.ctx, xs=ch.scales.x, ys=ch.scales.y;
var vx=xs.getPixelForValue(150), hy=ys.getPixelForValue(6);
ctx.save(); ctx.strokeStyle=N35; ctx.setLineDash([5,5]); ctx.lineWidth=1;
ctx.beginPath(); ctx.moveTo(vx,a.top); ctx.lineTo(vx,a.bottom); ctx.moveTo(a.left,hy); ctx.lineTo(a.right,hy); ctx.stroke();
ctx.setLineDash([]); ctx.fillStyle=N80; ctx.font="700 9.5px Inter";
ctx.textAlign="left"; ctx.fillText("COVER & SIMPLIFY", a.left+10, a.top+16);
ctx.textAlign="right"; ctx.fillText("MANAGE W/ STRUCTURED CRITERIA", a.right-10, a.top+16);
ctx.textAlign="left"; ctx.fillText("COVER & MONITOR", a.left+10, a.bottom-10);
ctx.textAlign="right"; ctx.fillText("RESTRICT / CASE-BY-CASE", a.right-10, a.bottom-10);
ctx.restore();
}},
{id:"blabels",afterDatasetsDraw:function(ch){
var ctx=ch.ctx; ctx.save(); ctx.font="600 10px Inter"; ctx.fillStyle=INK; ctx.textAlign="center";
ch.getDatasetMeta(0).data.forEach(function(el,i){ ctx.fillText(pts[i].l, el.x, el.y - pts[i].r - 6); });
ctx.restore();
}}]
});
}
/* --- Fig 3: Funnel --- */
function funnel(){
var stages=[
{l:"Request filed", v:12480, c:NAVY},
{l:"Documentation complete", v:10110, c:N80},
{l:"Clinical review initiated", v:8640, c:N55},
{l:"Interim accommodation granted", v:6905, c:N35},
{l:"Final approval sustained (12 mo)", v:5236, c:"rgba(17,24,39,.75)"}
];
var conv=[null,"81.0%","85.5%","79.9%","75.8%"];
new Chart(document.getElementById("fig3"),{
type:"bar",
data:{labels:stages.map(function(s){return s.l;}),
datasets:[{data:stages.map(function(s){return [-s.v/2, s.v/2];}),
backgroundColor:stages.map(function(s){return s.c;}),borderWidth:0,barPercentage:.62,categoryPercentage:1}]},
options:{indexAxis:"y",responsive:true,maintainAspectRatio:false,
plugins:{legend:{display:false},
tooltip:{backgroundColor:INK,padding:12,callbacks:{
label:function(c){var i=c.dataIndex; return " n = "+stages[i].v.toLocaleString("en-US")+(conv[i]?" · stage conversion "+conv[i]:"");}}}},
scales:{
x:{min:-7000,max:7000,ticks:{display:false},grid:{display:false}},
y:{grid:{display:false},ticks:{font:{size:11,weight:"600"}}}
}},
plugins:[{id:"flabels",afterDatasetsDraw:function(ch){
var ctx=ch.ctx; ctx.save();
ch.getDatasetMeta(0).data.forEach(function(bar,i){
ctx.font="700 12px Inter"; ctx.textAlign="center";
ctx.fillStyle = "#ffffff";
ctx.fillText(stages[i].v.toLocaleString("en-US"), bar.x, bar.y+4);
if(conv[i]){ ctx.font="600 10px Inter"; ctx.fillStyle=N80; ctx.textAlign="left";
ctx.fillText("→ "+conv[i], ch.chartArea.right-64, bar.y - bar.height/2 - 6); }
}); ctx.restore();
}}]
});
}
/* --- Fig 4: Radar --- */
function radar(){
new Chart(document.getElementById("fig4"),{
type:"radar",
data:{labels:["Pain severity","Sleep disruption","Functional limitation","Treatment-cost intensity","Administrative burden","Lost productivity"],
datasets:[
{label:"Migraine", data:[7.8,6.4,7.5,6.9,6.8,8.4], borderColor:NAVY, backgroundColor:"rgba(30,58,138,.14)", pointBackgroundColor:NAVY, borderWidth:2},
{label:"Postoperative recovery", data:[8.6,5.2,6.8,7.4,6.1,5.0], borderColor:INK, backgroundColor:"rgba(17,24,39,.08)", pointBackgroundColor:INK, borderWidth:2, borderDash:[6,4]},
{label:"Trauma spectrum", data:[6.1,7.8,8.0,5.4,7.6,7.2], borderColor:N55, backgroundColor:"rgba(30,58,138,.08)", pointBackgroundColor:N55, borderWidth:2},
{label:"Chronic insomnia", data:[3.5,9.0,6.2,4.8,5.5,7.0], borderColor:N35, backgroundColor:"rgba(30,58,138,.05)", pointBackgroundColor:N35, borderWidth:2}
]},
options:{responsive:true,maintainAspectRatio:false,
plugins:{legend:{position:"bottom",labels:{usePointStyle:true,boxWidth:8,font:{size:11},padding:18}},
tooltip:{backgroundColor:INK,padding:12}},
scales:{r:{min:0,max:10,ticks:{stepSize:2,backdropColor:"transparent",font:{size:9},color:"rgba(17,24,39,.55)"},
grid:{color:"rgba(17,24,39,.12)"},angleLines:{color:"rgba(17,24,39,.12)"},
pointLabels:{font:{size:11,weight:"600"},color:"#111827"}}}}
});
}
/* --- Fig 5: Premium trend --- */
function trend(){
var years=[2015,2016,2017,2018,2019,2020,2021,2022,2023,2024,2025];
new Chart(document.getElementById("fig5"),{
type:"line",
data:{labels:years,datasets:[
{label:"Family premium (avg)", data:[17545,18142,18764,19616,20576,21342,22221,23968,25570,26880,28250],
borderColor:NAVY, backgroundColor:"rgba(30,58,138,.10)", fill:true, tension:.35, pointRadius:2.6, pointBackgroundColor:NAVY, borderWidth:2.4},
{label:"Single premium (avg)", data:[6253,6435,6690,6896,7188,7470,7739,8435,8951,9400,9890],
borderColor:INK, borderDash:[6,4], tension:.35, pointRadius:2.4, pointBackgroundColor:INK, borderWidth:2, fill:false},
{label:"HDHP deductible (avg single)", data:[1544,1590,1630,1660,1690,1720,1745,1765,1787,1810,1840],
borderColor:N35, tension:.35, pointRadius:0, borderWidth:2, fill:false}
]},
options:{responsive:true,maintainAspectRatio:false,
plugins:{legend:{position:"bottom",labels:{usePointStyle:true,boxWidth:8,font:{size:11},padding:18}},
tooltip:{backgroundColor:INK,padding:12,callbacks:{label:function(c){return " "+c.dataset.label+": "+money(c.parsed.y);}}}},
scales:{
x:{grid:{display:false},ticks:{font:{size:10.5}}},
y:{grid:{color:"rgba(17,24,39,.08)"},ticks:{callback:function(v){return "$"+(v/1000)+"k";}}}
}}
});
}
/* --- Fig 6: Gantt --- */
function gantt(){
var QL=["Q1 ’25","Q2 ’25","Q3 ’25","Q4 ’25","Q1 ’26","Q2 ’26","Q3 ’26","Q4 ’26","Q1 ’27","Q2 ’27","Q3 ’27","Q4 ’27","Q1 ’28","Q2 ’28","Q3 ’28"];
var mk=function(a,b){return a.map(function(d){return {x:[d[0],d[1]],y:d[2]};});};
var reg = mk([[0,6,"Transparency enforcement escalation"],[3,10,"IRA negotiation round 2"],[5,12,"No Surprises arbitration refinements"],[7,14,"State copay-adjuster reform"]]);
var pay = mk([[2,9,"GLP-1 outcomes-based contracts"],[4,11,"CGRP step-therapy reform"],[8,14,"Site-neutral payment pilots"]]);
var ins = mk([[1,8,"Affordability navigation rollout"],[6,12,"NCAA-aligned waiver standard"],[9,14,"Trauma-informed documentation training"]]);
var mil = mk([[4.0,4.25,"IRA round-1 prices effective"],[10.0,10.25,"IRA round-2 price-setting"]]);
function ds(arr,color,bc){ return {data:arr.map(function(r){return [r.x[0],r.x[1]];}),
_rows:arr.map(function(r){return r.y;}), backgroundColor:color, borderColor:bc||color, borderWidth:1,
barPercentage:.55, categoryPercentage:1}; }
/* map rows to numeric y via labels on y-axis */
var rows=["Transparency enforcement escalation","IRA negotiation round 2","No Surprises arbitration refinements","State copay-adjuster reform",
"GLP-1 outcomes-based contracts","CGRP step-therapy reform","Site-neutral payment pilots",
"Affordability navigation rollout","NCAA-aligned waiver standard","Trauma-informed documentation training"];
function barData(arr){ return arr.map(function(r){ return {x:[r[0],r[1]], y:rows.indexOf(r[2])}; }); }
new Chart(document.getElementById("fig6"),{
type:"bar",
data:{datasets:[
{label:"Regulatory", data:barData(reg), backgroundColor:NAVY, barPercentage:.5, categoryPercentage:.9},
{label:"Payer", data:barData(pay), backgroundColor:N55, barPercentage:.5, categoryPercentage:.9},
{label:"Institutional", data:barData(ins), backgroundColor:N18, borderColor:NAVY, borderWidth:1, barPercentage:.5, categoryPercentage:.9},
{label:"Milestone", data:barData(mil), backgroundColor:INK, barPercentage:.9, categoryPercentage:.9, barThickness:3}
]},
options:{indexAxis:"y",responsive:true,maintainAspectRatio:false,parseDouble:false,
plugins:{legend:{position:"bottom",labels:{usePointStyle:true,boxWidth:8,font:{size:11},padding:16,
filter:function(i){return i.text!=="Milestone" || true;}}},
tooltip:{backgroundColor:INK,padding:12,callbacks:{
title:function(){return "";},
label:function(c){ var v=c.raw.x; return " "+c.dataset.label+" · "+QL[Math.round(v[0])]+" → "+QL[Math.min(14,Math.round(v[1]))];}}}},
scales:{
x:{min:0,max:14,grid:{color:"rgba(17,24,39,.07)"},
ticks:{stepSize:1,font:{size:9},callback:function(v){return QL[v]||"";}}},
y:{labels:rows, grid:{display:false}, ticks:{font:{size:10.5,weight:"600"},autoSkip:false}}
}}
});
}
/* lazy-build charts on visibility */
var figIds=["fig1","fig2","fig3","fig4","fig5","fig6"];
if("IntersectionObserver" in window && !reduced){
var fio = new IntersectionObserver(function(entries){
entries.forEach(function(en){ if(en.isIntersecting){ build(en.target.id); fio.unobserve(en.target);} });
},{rootMargin:"160px 0px"});
figIds.forEach(function(id){ var el=document.getElementById(id); if(el) fio.observe(el); });
}else{
figIds.forEach(build);
}
/* table bar widths animate on reveal */
setTimeout(function(){
document.querySelectorAll("td .bar i").forEach(function(b){ b.style.width = b.style.getPropertyValue("--w"); });
}, reduced?0:600);
})();
</script>
</body>
</html>